• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Acadia Pharmaceuticals to develop intranasal carbetocin for the treatment of hyperphagia in PWS

Acadia Pharmaceuticals announced that it will develop ACP-101 (formerly LV-101) intranasal carbetocin for the treatment of excessive hunger in Prader-Willi syndrome (PWS). Acadia acquired the rights to the nasal spray when it acquired Levo Therapeutics in June 2022. Levo had licensed the intranasal carbetocin from Ferring Pharmaceuticals in 2017 and initiated Phase 3 … [Read more...] about Acadia Pharmaceuticals to develop intranasal carbetocin for the treatment of hyperphagia in PWS

Moat Biotechnology raises $6.5 million for development of intranasal/inhaled COVID-19 vaccine

Moat Biotechnology (MoatBio), a spin-out from Tetherex Pharmaceuticals, announced that it has closed a funding round of more than $6.5 million following an initial funding led by Cortado Ventures in September 2022. The company says that it intends to use the proceeds for continued development of an inhaled/intranasal COVID-19 vaccine based on the SC-AdVax single-cycle … [Read more...] about Moat Biotechnology raises $6.5 million for development of intranasal/inhaled COVID-19 vaccine

Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury

Alpha Cognition announced that the Army Medical Research and Material Command has awarded the company a $750,000 grant to support a pre-clinical study of the possible use of ALPHA-1062 Intranasal galantamine for the treatment of blast-induced mild traumatic brain injury (mTBI). According to Alpha Cognition, the study will be conducted in partnership with the Seattle … [Read more...] about Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury

CQDM provides funding for Oragenics intranasal COVID-19 vaccine

According to Oragenics, Canadian biopharmaceutical research consortium CQDM has awarded a grant for development of variant-agnostic protein antigens for use in an intranasal COVID-19 vaccine that "aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1." According to the CQDM web site, the total value of the project is $1.64 million, with … [Read more...] about CQDM provides funding for Oragenics intranasal COVID-19 vaccine

Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients

Pneumagen said that it has closed an £8 million funding round, with proceeds going to support Phase 2 development of the company's Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, including a Phase 2b trial in COPD patients experiencing exacerbations caused by viral infection that is expected to be initiated in 2024. The company announced in … [Read more...] about Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients

Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials

Nephron Pharmaceuticals announced that the company is now offering 0.5% albuterol sulfate inhalation solution in 5 ml vials for direct shipping to US medical facilities in response to a nationwide shortage. Ritedose Pharmaceuticals recently announced that if would begin manufacturing 0.5% albuterol in response to the shortage. Nephron notes that has been manufacturing … [Read more...] about Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials

Pulmotect gets $8.9 million grant for Phase 2 trial of PUL-042 inhalation solution

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded an $8.9 million grant to Pulmotect for continued development of the company's PUL-042 immune stimulating inhalation solution, the company announced. Pulmotect said that the funds will go toward a Phase 2 trial titled, “A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 … [Read more...] about Pulmotect gets $8.9 million grant for Phase 2 trial of PUL-042 inhalation solution

Aerami says it will advance AER-901 inhaled imatinib into a Phase 2 trial for PAH and PH-ILD

Aerami Therapeutics said that pre-clinical and Phase 1 data presented recently at ATS support advancing the company's AER-901 nebulized imatinib into a Phase 2 trial that will include both patients with pulmonary arterial hypertension (PAH) and patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company said that it expects to … [Read more...] about Aerami says it will advance AER-901 inhaled imatinib into a Phase 2 trial for PAH and PH-ILD

Halo Therapeutics raises £1.5 million for Phase 1 trial of its pan-coronavirus antiviral nasal spray

Bristol University spinout Halo Therapeutics announced that it has raised £1.5 million in a funding round led by the Development Bank of Wales to support a Phase 1 trial of the company's HTLX-1 linoleic acid pan-coronavirus antiviral nasal spray. According to the company's web site, Halo is developing nasal formulations based on its free fatty acid technology for both … [Read more...] about Halo Therapeutics raises £1.5 million for Phase 1 trial of its pan-coronavirus antiviral nasal spray

SoftOx Solutions outsources development of SIS inhalation solution to the University of Copenhagen

SoftOx Solutions has announced a restructuring plan that includes shutting down its own GMP facility, laying off employees, and outsourcing further development of its SoftOx inhalation solution (SIS) to the University of Copenhagen. The company said that it would retain ownership of the IP and the commercial rights. In May 2022, SoftOx announced Phase 1 results … [Read more...] about SoftOx Solutions outsources development of SIS inhalation solution to the University of Copenhagen

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews